Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Avidity Biosciences Inc
RNA
Healthcare
Biotechnology
Avidity Biosciences, Inc. is a biopharmaceutical company. The Company is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs). The AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA...
therapies. Its advancing and expanding pipeline has three programs in clinical development. AOC 1001 is designed to treat people with myotonic dystrophy type 1 (DM1) and is in phase I/II development with the ongoing MARINA open label extension study (MARINA-OLE). AOC 1044 is designed for people with Duchenne muscular dystrophy and is in phase I/II development with the EXPLORE44 trial. AOC 1020 is designed to treat people living with facioscapulohumeral muscular dystrophy (FSHD) and is in Phase I/II development with the FORTITUDE trial.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:RNA)
New Post
View:
Posts & Comments
Threaded Posts
(276)
•••
whytestocks
X
Post by
whytestocks
on Aug 09, 2024 4:17pm
Avidity Biosciences Reports Second Quarter 2024 Financial Re
Breaking News: $RNA Avidity Biosciences Reports Second Quarter 2024 Financial Results and Recent HighlightsAvidity Biosciences Reports Second Quarter 2024 Financial Results and Recent Highlights PR
...more
(276)
•••
whytestocks
X
Post by
whytestocks
on Aug 09, 2024 12:00pm
Avidity Biosciences Announces Positive AOC 1044 Data Demonst
Breaking News: $RNA Avidity Biosciences Announces Positive AOC 1044 Data Demonstrated Significant Increase of 25% in Dystrophin Production and Reduction of Creatine Kinase Levels to Near Normal in
...more
(9)
•••
MikeTester
X
Post by
MikeTester
on Aug 03, 2024 6:16am
Avidity Biosciences, Inc. (NASDAQ:RNA): Pioneering the Next
https://beyondspx.com/2024/08/02/avidity-biosciences-inc-nasdaqrna-pioneering-the-next-generation-of-rna-therapeutics/
(276)
•••
whytestocks
X
Post by
whytestocks
on Jun 12, 2024 10:30am
Casey's Reports Upbeat Earnings, Joins Avidity Biosciences,
JUST IN: $RNA Casey's Reports Upbeat Earnings, Joins Avidity Biosciences, Rentokil Initial And Other Big Stocks Moving Higher On Wednesday | BenzingaU.S. stocks were higher, with the Nasdaq
...more
(0)
•••
PressRelease
X
Post by
PressRelease
on Dec 15, 2022 7:38pm
New Press Release - Avidity Biosciences, Inc. Announces Pricing of Upsized Public Offering of Common Stock
SAN DIEGO, Dec. 15, 2022 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced the pricing of an underwritten public offering of 12,000,000...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Dec 15, 2022 7:01am
New Press Release - Avidity Biosciences, Inc. Announces Proposed Public Offering of Common Stock
SAN DIEGO, Dec. 15, 2022 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that it intends to offer and sell, subject to market and other...
read article.
(72)
•••
Iseneschal
X
Post by
Iseneschal
on Dec 14, 2022 2:02pm
RNA ..... Scalped ... Yehha !
cheers
(72)
•••
Iseneschal
X
Post by
Iseneschal
on Dec 14, 2022 1:59pm
RNA ....vols are increasing
Needs to break $18 and this will be heroic !
(72)
•••
Iseneschal
X
Post by
Iseneschal
on Dec 14, 2022 1:57pm
RNA .... Tick by Tick call ; )
$17.85 LoL
(72)
•••
Iseneschal
X
Post by
Iseneschal
on Dec 14, 2022 1:52pm
RNA ..... Lets go !!!!
$17.70
(72)
•••
Iseneschal
X
Post by
Iseneschal
on Dec 14, 2022 1:48pm
RNA .....it's walkin
$17.35
(72)
•••
Iseneschal
X
Post by
Iseneschal
on Dec 14, 2022 1:44pm
RNA ....got it sub $17 ; )
Need to break $17.85.....hard
(72)
•••
Iseneschal
X
Post by
Iseneschal
on Dec 14, 2022 1:42pm
RNA ...small position here !
Cheers !
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Introducing the NEW DealRoom: Your Gateway to Capital-Raising Investments
Debt-Free Cannabis Company Set for Next Stage of Growth
Are PGM mining stocks an attractive area for your next portfolio allocation?
ReGen III Appoints New CEO and President to Accelerate Commercial and Strategic Opportunities
Rig Count Soars as Utilization Surpasses Industry Averages
Learn How this Company is Disrupting Point-of-Care Testing
Unique Battery Metals opportunity in Quebec
Discover Options Trading Strategies to Minimize your Tax Burden